BioInvent International AB
STO:BINV
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
BioInvent International AB
Free Cash Flow
BioInvent International AB
Free Cash Flow Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Free Cash Flow | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
BioInvent International AB
STO:BINV
|
Free Cash Flow
-kr257.1m
|
CAGR 3-Years
-70%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
-13%
|
|
|
Biogaia AB
STO:BIOG B
|
Free Cash Flow
kr303m
|
CAGR 3-Years
0%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
Bonesupport Holding AB
STO:BONEX
|
Free Cash Flow
kr216.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vitrolife AB
STO:VITR
|
Free Cash Flow
kr388m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
3%
|
CAGR 10-Years
9%
|
|
|
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
|
Free Cash Flow
kr5.4B
|
CAGR 3-Years
20%
|
CAGR 5-Years
38%
|
CAGR 10-Years
31%
|
|
|
BioArctic AB
STO:BIOA B
|
Free Cash Flow
kr1.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
BioInvent International AB
Glance View
BioInvent International AB engages in the research and development of novel and immuno-modulatory antibodies for the treatment of cancer. The company is headquartered in Lund, Skane and currently employs 84 full-time employees. The company went IPO on 2001-06-12. The Company’s operational activities are focused on expanding the clinical development of human antibodies, such as BI-1206, BI-1808, BI-1607 and BT-001. The firm has one wholly-owned subsidiary BioInvent Finans AB, which engaged in the administration of warrants issued by the Company.
See Also
What is BioInvent International AB's Free Cash Flow?
Free Cash Flow
-257.1m
SEK
Based on the financial report for Dec 31, 2025, BioInvent International AB's Free Cash Flow amounts to -257.1m SEK.
What is BioInvent International AB's Free Cash Flow growth rate?
Free Cash Flow CAGR 10Y
-13%
Over the last year, the Free Cash Flow growth was 34%. The average annual Free Cash Flow growth rates for BioInvent International AB have been -70% over the past three years , -30% over the past five years , and -13% over the past ten years .
